Patents by Inventor Max V. Rasmussen

Max V. Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10865389
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: December 15, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10858633
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 8, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10858634
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 8, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10829770
    Abstract: Polynucleotides encoding fusion proteins contain a secretable luciferase fused to a modified polypeptide of interest are disclosed. The polypeptide of interest has been modified to remove a native N-terminal secretion sequence and has been replaced by the secretable luciferase. One example of a modified polypeptide of interest is interferon. The polynucleotides and fusion proteins have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields. Methods for producing the secretable fusion protein are also disclosed.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 10, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Publication number: 20200002707
    Abstract: Polynucleotides encoding fusion proteins contain a secretable luciferase fused to a modified polypeptide of interest are disclosed. The polypeptide of interest has been modified to remove a native N-terminal secretion sequence and has been replaced by the secretable luciferase. One example of a modified polypeptide of interest is interferon. The polynucleotides and fusion proteins have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields. Methods for producing the secretable fusion protein are also disclosed.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 2, 2020
    Applicant: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10435695
    Abstract: Polynucleotides encoding fusion proteins comprising interferons and luciferases which have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: October 8, 2019
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10385319
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: August 20, 2019
    Assignee: The Governement of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Publication number: 20190233799
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Application
    Filed: March 28, 2019
    Publication date: August 1, 2019
    Applicant: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Publication number: 20190218526
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Applicant: The Government of the United States of America, as represented by the Secretary of Homeland Securit
    Inventors: Michael Puckette, Max V. Rasmussen
  • Publication number: 20190218525
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P 1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 18, 2019
    Applicant: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Publication number: 20180066235
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Application
    Filed: September 8, 2016
    Publication date: March 8, 2018
    Applicant: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Publication number: 20180066267
    Abstract: Polynucleotides encoding fusion proteins comprising interferons and luciferases which have biotherapeutic, diagnostic, and quality control applications in biotechnological, medical, and veterinary fields.
    Type: Application
    Filed: May 1, 2017
    Publication date: March 8, 2018
    Applicant: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen